Patents by Inventor Ralph C. Haltiwanger

Ralph C. Haltiwanger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of PARP inhibitors
    Patent number: 10150772
    Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 11, 2018
    Assignee: CEPHALON, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
    Patent number: 9987281
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 5, 2018
    Assignee: IGNYTA, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR
    Publication number: 20170290833
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Applicant: IGNYTA, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • CRYSTALLINE FORMS OF PARP INHIBITORS
    Publication number: 20170267683
    Abstract: The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.
    Type: Application
    Filed: November 25, 2015
    Publication date: September 21, 2017
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
  • Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
    Patent number: 9718810
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 1, 2017
    Assignee: IGNYTA, INC.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • PYRROLOTRIAZINES AS ALK INHIBITORS
    Publication number: 20160347756
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 1, 2016
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Pyrrolotriazines as ALK inhibitors
    Patent number: 9440984
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 13, 2016
    Assignee: Cephalon, Inc.
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Solid state forms of a quinazoline derivative and its use as a BRAF inhibitor
    Patent number: 9353097
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: May 31, 2016
    Assignee: Ignyta, Inc.
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • PYRROLOTRIAZINES AS ALK INHIBITORS
    Publication number: 20160068535
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • SOLID STATE FORMS OF A QUINAZOLINE DERIVATIVE AND ITS USE AS A BRAF INHIBITOR
    Publication number: 20150376171
    Abstract: This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
    Type: Application
    Filed: June 22, 2015
    Publication date: December 31, 2015
    Inventors: Stephen J. Bierlmaier, Ralph C. Haltiwanger, Martin J. Jacobs
  • Solid State Forms of 6-[4-[3-((R)-2-Methylpyrrolidine-1-yl)-propoxy]phenyl] 2H-pyridazine-3-one Hydrochloride
    Publication number: 20140275102
    Abstract: Solid state forms of the compound 6-[4-[3-((R)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2H-pyridazine-3-one hydrochloride (Compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine H3 receptor antagonist/inverse agonist. Thus the provided solid state forms are useful, for example, for the manufacture of a medicament for the treatment of disorders mediated by the H3 receptor.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: CEPHALON, INC.
    Inventors: Stephen J. Bierlmaier, Laurent Courvoisier, Ralph C. Haltiwanger, Martin J. Jacobs